Remus Pharmaceuticals Limited — Others, 10-01-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Remus Pharmaceuticals has announced a board meeting to disclose the Reconciliation of Share Capital Audit Report for the quarter ended December 31, 2024. The report confirms an issued equity share capital of 58,92,000 shares, fully dematerialized and recorded with NSDL and CDSL, ensuring a streamlined capital structure.

This audit underlines the company's adherence to share capital regulations, which could enhance investor confidence in operational integrity. Investors may view this as a positive outlook for governance and transparency, highlighting the company's commitment to maintaining accurate share records and regulatory compliance.